Which PK model best describes a drug that is activated in the liver to form an active metabolite, requiring formation and clearance terms for both parent and metabolite?

• A. A parent–to–metabolite model with sequential formation and clearance terms (Vf, CLparent, CLmet), including possible nonlinearities (Km/Vmax).
• B. A simple parent-only clearance model ignoring the metabolite.
• C. A two-metabolite model with no formation rate term.
• D. A fixed-dose model assuming instantaneous activation and no clearance.

Answer: (A)

The key idea is to represent the drug as it is activated in the liver to a separate active metabolite, with explicit processes for making the metabolite and for clearing both the parent and the metabolite. A model that includes a formation term for converting the parent into the active metabolite (often noted as Vf) along with separate clearance terms for the parent (CL_parent) and for the metabolite (CL_met) directly mirrors this biology. If you add nonlinear kinetics (Km and Vmax), you can capture saturable activation—where the rate of metabolism changes with concentration—which is common in hepatic activation pathways. This structure lets you describe how the parent is reduced as it forms the metabolite, how the metabolite appears and is cleared, and how their concentrations relate over time, all of which are essential when the therapeutic effect comes from the metabolite.

Other models fall short because they either ignore the metabolite altogether, or miss the formation step that creates the active metabolite from the parent, or assume instantaneous activation with no subsequent clearance. A simple parent-only clearance approach cannot account for the presence and kinetics of the active metabolite. A model with two metabolites but no formation term lacks the mechanism to generate those metabolites from the parent. A fixed-dose, instantaneous-activation model removes the dynamic processes of formation and elimination entirely, failing to describe how concentrations change over time after dosing.